News

A new study conducted in London suggests that exposure to air pollution is enough to counter the health benefits of exercise in adults age 60 or older regardless of whether they have chronic obstructive pulmonary disease (COPD), heart disease, or are healthy. These findings stem from one of two…

Long-term use of Tudorza (aclidinium bromide) can significantly and safely reduce exacerbations in people with moderate to severe chronic obstructive pulmonary disease and cardiovascular disease or risk factors, findings in a Phase 4 post-marketing study show. Tudorza, developed by AstraZeneca, contains the long-acting muscarinic antagonist (LAMA) aclidinium bromide,…

The common tool used to assess which chronic obstructive pulmonary disease (COPD) patients are most in need of a lung transplant may underestimate how long people survive if they do not get new lungs. The findings, published in the journal Chest, suggest that the tool, called BODE, might cause…

A lung transplant increases COPD patients’ risk of developing cancer, a Swedish study indicates. The research, “Risk of cancer after lung transplantation for COPD,” was published in the International Journal of Chronic Obstructive Pulmonary Disease. Transplants increase the odds that people with some end-stage lung diseases…

Results from Novartis’ FLASH clinical trial show that switching patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) from treatment with Seretide to Ultibro Breezhaler improved lung function. Ultibro Breezhaler was also found to be well-tolerated by patients. Seretide is an inhaled corticosteroid, and its long-term use can be associated with several side…

Propeller Health and Express Scripts recently signed an agreement to provide a novel digital respiratory care solution to help manage chronic obstructive pulmonary disease (COPD) and asthma. Propeller developed a digital solution that combines inhaler sensors with a proprietary software platform that can be used as…

The COPD therapy-development partners Theravance Biopharma and Mylan have submitted a New Drug Application for revefenacin (TD-4208) to the U.S. Food and Drug Administration. Revefenacin is a long-lasting mist. The partners designed it so that chronic obstructive pulmonary disease need to take it only once a day. The therapy is called…

Boehringer Ingelheim will host a live event on Facebook and Twitter on Nov. 15 — World COPD Day — to increase awareness about how people with chronic obstructive pulmonary disease (COPD) can improve their quality of life. This year’s World COPD Day is led by the Global Initiative for…

Verona Pharma has enrolled more than half of the 400 COPD patients it is seeking for a Phase 2b clinical trial of its therapy candidate RPL554, putting the program ahead of schedule. This means the company may be able to report the results of the study by mid-2018, sooner than expected. The…

GlaxoSmithKline (GSK) and Innoviva recently presented positive results of a study showing that Anoro Ellipta is more effective than Stiolto Respimat in symptomatic patients with chronic obstructive pulmonary disease (COPD). The results were presented at the 2017 CHEST Annual Meeting of the American College of Chest Physicians in Toronto, Canada,…